Kiawah Eye Meeting

Kiawah Eye Meeting

Source:

Lindstrom RL. Thoughts on the future of cataract surgery. Presented at: Kiawah Eye; June 3-5, 2021; Kiawah Island, S.C.

Disclosures: Lindstrom reports he has relevant financial disclosures with AcuFocus, Alcon, Bausch + Lomb, Foresight Vision, Johnson & Johnson Vision and Zeiss. He also credits Market Scope for providing data and assistance with the development of his lecture.
June 07, 2021
1 min read
Save

Lindstrom: Future of cataract surgery in US includes bilateral, in-office procedures

Source:

Lindstrom RL. Thoughts on the future of cataract surgery. Presented at: Kiawah Eye; June 3-5, 2021; Kiawah Island, S.C.

Disclosures: Lindstrom reports he has relevant financial disclosures with AcuFocus, Alcon, Bausch + Lomb, Foresight Vision, Johnson & Johnson Vision and Zeiss. He also credits Market Scope for providing data and assistance with the development of his lecture.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

KIAWAH ISLAND, S.C. — Depending on a number of different scenarios, the future of cataract surgery in the U.S. will include in-office immediate sequential bilateral cataract surgery.

In his keynote lecture at Kiawah Eye, Richard L. Lindstrom, MD, said that a number of innovations and changes, such as greater implantation of the Light Adjustable Lens (RxSight) and changing reimbursement, will lead to widespread adoption of in-office ISBCS.

Richard L. Lindstrom

An aging, more active, growing population of people seeking cataract surgery will lead to these and other innovations, according to Lindstrom. He projected by 2030 the demand for 6 million cataract surgeries a year compared with 4 million in 2019, being performed by about 10,000 ophthalmologists, roughly the same number as in 2019.

He sees a split of 60% monofocal IOL implantations to 40% premium IOLs.

“The top-of-the-line premium IOL in 2030 will be an adjustable, accommodating IOL with reduced PCO in an automated, single-use, preloaded injector,” Lindstrom said.

He also projected that phacoemulsification will evolve into phacoaspiration due to technologies such as the CataPulse (Med-Logics), miLOOP (Zeiss) and miPORT (Zeiss), obviating the need for phacoemulsification energy delivered to the eye.